AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test

Grand News Network | November 7, 2023

Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the detection and diagnosis of colorectal cancer (CRC). 

Key attributes of EMERGE that make it superior to mainstream AI and machine learning analytical solutions include its computational speed, ability to handle millions of variables, and ability to operate agnostically without any assumptions or constraints.

The partnership expands on Mainz Biomed's initial deployment of EMERGE for examining the ColoFuture study's findings, which revealed promising results, including a 94% sensitivity for ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner